FFO
OVID icon

Fortitude Family Office’s Ovid Therapeutics OVID Stock Holding History

Fortitude Family Office’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$839 Hold
312
– – ﹤0.01% 1806
2026
Q1 		$693 Buy
+312
New +$558 ﹤0.01% 1611

Other funds holding OVID

PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
BMC
Benin Management Corp Wilton, Connecticut $494M AUM 25.95% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
AWA
Aaron Wealth Advisors Chicago, Illinois $1.97B AUM 36.91% 1-Year Est. Return
TFM
TFC Financial Management Boston, Massachusetts $902M AUM 21.74% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Fortitude Family Office's OVID Position: Q2 2026 in Review

Fortitude Family Office held its Ovid Therapeutics (OVID) position steady in Q2 2026 at 312 shares worth $839. The position accounts for ﹤0.01% of the portfolio, ranked #1806.

Fortitude Family Office first reported a position in OVID in Q1 2026 and has held it in 2 quarters since. 7 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • Fortitude Family Office held 312 shares of Ovid Therapeutics worth $839 as of Q2 2026.
  • Fortitude Family Office left its Ovid Therapeutics share count unchanged in Q2 2026.
  • Ovid Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1806 holding.
  • Fortitude Family Office first reported a position in Ovid Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 7 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.